Search CTL/CD8+ T-Cell Epitope Database

Found 27 matching records:

Displaying record number 61193

HXB2 Location	Gag(114-122) p17(114-122) DNA(1129..1155)	Gag Epitope Map
Author Location	p17
Epitope	`KTQQAAADK`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*57)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Variable epitope KTQQAAADK was included in tHIVconsvX. It was found in only 1% of 4,300 sequences, with its variant, KaQQAAADt being found in 1411/4300 (12%) of sequences in the database.

References

Ondondo2016 Beatrice Ondondo, Hayato Murakoshi, Genevieve Clutton, Sultan Abdul-Jawad, Edmund G.-T. Wee, Hiroyuki Gatanaga, Shinichi Oka, Andrew J. McMichael, Masafumi Takiguchi, Bette Korber, and Tomáš Hanke. Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Mol. Ther., 24(4):832-842, Apr 2016. PubMed ID: 26743582. Show all entries for this paper.

Displaying record number 61139

HXB2 Location	Gag(177-187) p24(45-55) DNA(1318..1350)	Gag Epitope Map
Author Location
Epitope	`EGATPQDLNTM`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope EGATPQDLNTM was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61140

HXB2 Location	Gag(177-187) p24(45-55) DNA(1318..1350)	Gag Epitope Map
Author Location
Epitope	`EGATPQDLNMM`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope EGATPQDLNMM was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61141

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location
Epitope	`TPQDLNTML`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope TPQDLNTML was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61142

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location
Epitope	`TPQDLNMML`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope TPQDLNMML was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61138

HXB2 Location	Gag(197-205) p24(65-73) DNA(1378..1404)	Gag Epitope Map
Author Location
Epitope	`AMQMLKDTI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope AMQMLKDTI was present in mosaic 1, being immunodominant in response but eliciting a weaker response than its variant AMQMLKeTI in Mosaic 2.

References

Displaying record number 61137

HXB2 Location	Gag(197-205) p24(65-73) DNA(1378..1404)	Gag Epitope Map
Author Location
Epitope	`AMQMLKETI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope AMQMLKETI was present in mosaic 2, being immunodominant in response and eliciting a stronger response than its variant AMQMLKDTI in Mosaic 1.

References

Displaying record number 61143

HXB2 Location	Gag(198-205) p24(66-73) DNA(1381..1404)	Gag Epitope Map
Author Location
Epitope	`MQMLKDTI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope QMLKDTINEEA was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61144

HXB2 Location	Gag(198-205) p24(66-73) DNA(1381..1404)	Gag Epitope Map
Author Location
Epitope	`MQMLKETI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope MQMLKETI was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61146

HXB2 Location	Gag(199-209) p24(67-77) DNA(1384..1416)	Gag Epitope Map
Author Location
Epitope	`QMLKETINEEA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope QMLKETINEEA was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61145

HXB2 Location	Gag(199-209) p24(67-77) DNA(1384..1416)	Gag Epitope Map
Author Location
Epitope	`QMLKDTINEEA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope QMLKDTINEEA was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61195

HXB2 Location	Gag(202-210) p24(70-78) DNA(1393..1419)	Gag Epitope Map
Author Location	Gag
Epitope	`KDTINEEAA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*40)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Highly conserved epitope KDTINEEAA was included in tHIVconsvX. It was found in 41% of 4,300 sequences, with its variant, KeTINEEAA being found in 50% of sequences in the database. Since both epitopes are present in the vaccine, combined coverage is 91%.

References

Displaying record number 61194

HXB2 Location	Gag(202-210) p24(70-78) DNA(1393..1419)	Gag Epitope Map
Author Location	Gag
Epitope	`KETINEEAA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*40)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Highly conserved epitope KETINEEAA was included in tHIVconsvX. It was found in 50% of 4,300 sequences, with its variant, KdTINEEAA being found in 41% of sequences in the database. Since both epitopes are present in the vaccine, combined coverage is 91%.

References

Displaying record number 61196

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location	Gag
Epitope	`TSTLQEQIGW`	Epitope Alignment
		Show epitope variants
Epitope Name	TW10
Subtype	B
Species (MHC/HLA)	human, mouse(B*57)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Moderately conserved epitope TSTLQEQIGW was included in tHIVconsvX. It was found in 40% of 4,300 sequences, with its variant, TSTLQEQIaW being found in 23% of sequences in the database. Since both epitopes are present in the vaccine and recognized, combined coverage is 63%.

References

Displaying record number 61149

HXB2 Location	Gag(275-282) p24(143-150) DNA(1612..1635)	Gag Epitope Map
Author Location
Epitope	`RMYSPVSI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope RMYSPVSI was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61147

HXB2 Location	Gag(275-282) p24(143-150) DNA(1612..1635)	Gag Epitope Map
Author Location
Epitope	`RMYSPTSI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope RMYSPTSI was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61150

HXB2 Location	Gag(316-323) p24(184-191) DNA(1735..1758)	Gag Epitope Map
Author Location
Epitope	`WMTDTLLV`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope WMTDTLLV was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61148

HXB2 Location	Gag(316-323) p24(184-191) DNA(1735..1758)	Gag Epitope Map
Author Location
Epitope	`WMTETLLV`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*5201)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope WMTETLLV was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61151

HXB2 Location	Gag(327-337) p24(195-205) DNA(1768..1800)	Gag Epitope Map
Author Location
Epitope	`NPDCKTILRAL`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope NPDCKTILRAL was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61152

HXB2 Location	Gag(327-337) p24(195-205) DNA(1768..1800)	Gag Epitope Map
Author Location
Epitope	`NPDCKTILKAL`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*6701)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope NPDCKTILKAL was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61153

HXB2 Location	Gag(341-349) p24(209-217) DNA(1810..1836)	Gag Epitope Map
Author Location
Epitope	`ATLEEMMTA`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human, mouse(A*0206)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope ATLEEMMTAL was present in mosaics 1 and 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61159

HXB2 Location	Pol(132-140) Protease(76-84) DNA(2478..2504)	Pol Epitope Map
Author Location
Epitope	`LIGPTPVNI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope LIGPTPVNI was present in mosaic 2, being immunodominant in response but eliciting a weaker response than its variant LvGPTPVNI in Mosaic 1.

References

Displaying record number 61158

HXB2 Location	Pol(132-140) Protease(76-84) DNA(2478..2504)	Pol Epitope Map
Author Location
Epitope	`LVGPTPVNI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope LVGPTPVNI was present in mosaic 1, being immunodominant in response and eliciting a stronger response than its variant LiGPTPVNI in Mosaic 2.

References

Displaying record number 61154

HXB2 Location	Pol(783-791) Integrase(68-76) DNA(4431..4457)	Pol Epitope Map
Author Location
Epitope	`LEGKIILVA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*4006)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade
Adjuvant	gp41 N-HR and C-HR helical peptides

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope LEGKIILVA was present in mosaic 2 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61155

HXB2 Location	Pol(783-791) Integrase(68-76) DNA(4431..4457)	Pol Epitope Map
Author Location
Epitope	`LEGKVILVA`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*4006)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade
Adjuvant	gp41 N-HR and C-HR helical peptides

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope LEGKVILVA was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61156

HXB2 Location	Pol(912-919) Integrase(197-204) DNA(4818..4841)	Pol Epitope Map
Author Location
Epitope	`GERIIDII`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*4002)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade
Adjuvant	gp41 N-HR and C-HR helical peptides

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Epitope GERIIDII was present in mosaic 1 of the second generation tHIVconsvX vaccine.

References

Displaying record number 61157

HXB2 Location	Pol(912-919) Integrase(197-204) DNA(4818..4841)	Pol Epitope Map
Author Location
Epitope	`GERIVDII`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human, mouse(B*4002)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine-induced immune responses, vaccine antigen design

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA), adenovirus
Vaccine strain	B clade
Adjuvant	gp41 N-HR and C-HR helical peptides

Notes

Using 3 strategies, (1) in silico-designed multivalent-mosaic proteins for greater breadth, magnitude, cross-reactivity (2) highly conserved epitopes for loss of replicative fitness and oligofunctional inter-clade specific T-cell production (3) beneficial CTL epitopes associated with low viral load (VL) for broad immune response; a conserved bivalent-mosaic immunogen, tHIV-consvX, was designed and vectored by plasmid DNA, ChAdOx1, and MVA for testing in mice and humans. Strong preclinical immunogenicity was seen in mice and in 120 untreated, chronic HIV-1 patients, tHIVconsvX-specific CTLs correlated with high CD4+ T cell count but not VL.
Env was excluded from this second generation vaccine as its short, conserved stretch has no beneficial epitopes and while its epitopes are immunodominant, they are not associated with good control of viremia.
Protective Japanese epitope GERIVDII was present in mosaic 2 of the second generation tHIVconsvX vaccine.